SCHEMBL2229320

SCHEMBL2229320

c1ccc2ncc(OCC3CCNC3)cc2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 6/20 0.69
SLC6A4 P31645 6/20 0.69
SLC6A3 Q01959 3/20 0.69
KCNH2 Q12809 4/20 0.57
HTR3A P46098 2/20 0.57
CHRNB2 P17787 3/20 0.53
CHRNA4 P43681 2/20 0.53
EP300 Q09472 1/20 0.51
KDM1A O60341 5/20 0.47
RCOR1 Q9UKL0 1/20 0.47
PRKCZ Q05513 2/20 0.46
MAOB P27338 1/20 0.45
IKBKB O14920 1/20 0.43
CHUK O15111 1/20 0.43
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
MAP2K1 Q02750 1/20 0.42
CHRNB1 P11230 1/20 0.42
CHRNB4 P30926 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2227832 0.82 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL2228515 0.82 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL2227826 0.82 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL4786058 0.78 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL35429 0.77 SLC6A2 (0.69) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL27972144 0.77 SLC6A2 (0.69) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL8439710 0.76 CHRNB2 (0.59) CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3
Hydrochloric Acid SCHEMBL8437890 0.75 CHRNB2 (0.61) CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3
SCHEMBL7459666 0.75 CHRNB2 (0.67) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL2229867 0.75 SLC6A2 (0.71) SLC6A2SLC6A4SLC6A3KCNH2HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US disclosed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP disclosed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US disclosed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION PRMT9, PRMT8, CBR1 SLC6A2 2876/4885SLC6A4 3841/4885SLC6A3 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.